Wuhan Brightrun Pharmaceutical Technology Co., Ltd.
BRH
Product
News
In the fields of diabetes and obesity treatment, GLP-1 receptor agonists have undoubtedly emerged as a shining star. Drugs such as semaglutide, liraglutide, exenatide, and tirzepatide are reshaping the lives of hundreds of millions of patients worldwide, thanks to their remarkable blood sugar-lowering and weight-loss effects.
Keywords:Bryheng Peptide Analysis Platform